指南与共识术前评估与围术期医学

权衡证据与SPAQI建议:SGLT2抑制剂从围术期停用转向继续使用

Balancing the evidence with the SPAQI recommendations: from perioperative discontinuation towards continuation of SGLT2 inhibitors.
指南 / 共识 · Br J Anaesth · 2026-06-12

围术期评估与质量改进学会(SPAQI)共识建议根据手术类型、代谢状态和基础适应证制定SGLT2抑制剂的围术期管理策略。该风险分层方法在正血糖性酮症酸中毒的低但真实风险与已确立的心肾获益之间取得平衡。现有证据有限,提示正血糖性酮症酸中毒更多由代谢状态(尤其是糖尿病和禁食)驱动,而非仅由继续用药所致。

要点

  • SPAQI共识推荐基于手术类型、代谢状态和适应证进行风险分层的SGLT2抑制剂围术期管理。
  • 正血糖性酮症酸中毒风险更多与糖尿病和禁食等代谢因素相关,而非单纯继续用药。
  • 停药可能导致心血管获益丧失,新兴数据提示继续用药可能有围术期获益但证据有限。

核心结论

  • SPAQI共识建议转向基于正血糖性酮症酸中毒风险因素和仔细代谢监测的策略,而非系统停药,有待大型随机对照试验。

研究设计与样本

  • SPAQI共识推荐,基于手术类型、代谢状态和基础适应证制定SGLT2抑制剂围术期管理策略。

主要发现

  • 现有证据有限,提示正血糖性酮症酸中毒更多由代谢状态(尤其是糖尿病和禁食)驱动,而非仅由继续用药所致。
  • 停药可能导致心血管获益丧失,而新兴数据提示继续用药可能有围术期获益,但证据仍有限。

关键数值与推荐

  • SPAQI共识推荐根据手术类型、代谢状态和基础适应证进行风险分层管理SGLT2抑制剂。

临床怎么用

  • 临床应基于正血糖性酮症酸中毒风险因素和仔细代谢监测来决定SGLT2抑制剂围术期是否继续,而非系统停药。

局限性

  • 当前证据有限,需大型随机对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Society for Perioperative Assessment and Quality Improvement consensus recommends a perioperative management strategy for sodium-glucose cotransporter 2 inhibitors based on surgical type, metabolic context, and underlying indication. This risk-stratified approach balances the low but real risk of euglycaemic ketoacidosis against established cardio-renal benefits. Current evidence is limited and suggests that euglycaemic ketoacidosis is driven more by metabolic context, particularly diabetes mellitus and fasting, than by drug continuation alone. Importantly, discontinuation could lead to a loss of cardiovascular benefit, whereas emerging data suggest potential perioperative benefits, although evidence remains limited. Overall, these recommendations shift toward a strategy based on euglycaemic ketoacidosis risk factors and careful metabolic monitoring rather than systematic discontinuation pending large randomised controlled trials.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Garcia B, Dixit AA, Legrand M, et al. Balancing the evidence with the SPAQI recommendations: from perioperative discontinuation towards continuation of SGLT2 inhibitors. Br J Anaesth. 2026. PMID: 42276948. doi:10.1016/j.bja.2026.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。